RecruitingPhase 2NCT00409435
A Study of Pyridostigmine in Postural Tachycardia Syndrome
Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome
Sponsor
Mayo Clinic
Enrollment
50 participants
Start Date
Oct 1, 2006
Study Type
INTERVENTIONAL
Conditions
Summary
This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.
Eligibility
Min Age: 15 YearsMax Age: 55 Years
Inclusion Criteria4
- Diagnosis of postural tachycardia syndrome using the following criteria:
- Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt.
- Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking.
- Both criteria must be fulfilled.
Exclusion Criteria6
- Pregnant or lactating women
- Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study
- Hypothyroidism or hyperthyroidism
- Clinically significant coronary artery disease
- Medications that could interfere with autonomic testing
- Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGpyridostigmine
one 180 mg capsule per day for 3 days
DRUGPlacebo
one capsule per day for 3 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT00409435
Related Trials
Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities?
NCT056180541 location
Inappropriate Sinus Tachycardia Registry
NCT0510763510 locations
Autoimmune Basis for Postural Tachycardia Syndrome
NCT050430511 location
POTS Adrenergic Ab (CIHR Aims #1&2)
NCT026739961 location
Autonomic Small Fiber Neuropathy and Ehlers Danlos Syndromes - Prospective Study and Registry
NCT043106441 location